ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1141

Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis

Rachel E. Sobel1, D. J. Lovell2, Hermine Brunner3, Jennifer E. Weiss4, Paula W. Morris5, Beth S. Gottlieb6, Elizabeth C. Chalom7, Lawrence K. Jung8, Karen Onel9, Lisa Petinoit10, Donald P. Goldsmith11, Staci Abramsky-Risman12, James P., Young13 and Edward H. Giannini14, 1Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology, Hackensack Univ Med Ctr, Hackensack, NJ, 5Pediatrics, Univ of Arkansas for Med Sci, Little Rock, AR, 6Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 7Pediatrics, St. Barnabas Medical Center, Livingston, NJ, 8Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Pediatric Rheumatology, 'Specially for Children, Dell Children's Medical Center, Austin, TX, 11Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13United BioSource Corporation, Ann Arbor, MI, 14Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: COX inhibitors, juvenile idiopathic arthritis (JIA), nonsteroidal antiinflammatory drugs (NSAIDs) and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17 years in December, 2006.  As a condition of approval, Pfizer conducted a Phase IV study, the Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry (SINCERE), to collect longer-term safety and developmental data on patients with JIA treated in routine clinical practice with celecoxib or non-selective NSAIDs (nsNSAIDs).

Methods: Children aged between 2 and 18 years with RF(+) or RF(-) polyarthritis, persistent or extended oligoarthritis, or systemic juvenile arthritis (without features of extra-articular features for ≥6 months) were enrolled into this prospective, observational, multi-centered, standard-of-care registry.  To be eligible, patients had to be receiving newly or recently prescribed (≤6 months) nsNSAID or celecoxib.  Duration of previous nsNSAID or celecoxib exposure, or use of concomitant DMARD or biologic therapy did not affect eligibility.  Once enrolled, patients were to remain in the study whether they continued on the original NSAID, switched, or discontinued NSAIDs altogether.  Visits were scheduled at 0, 4, 8, 12 months, and at 6 month intervals thereafter for a minimum of 2 years.  All adverse events (AEs) regardless of severity were captured in the SINCERE database. 

Results: A total of 274 patients (219 in the nsNSAID and 55 in the celecoxib group) were observed for 410 patient-years of observation (PYO) at study termination.  Sixty percent of patients in the celecoxib group, and 53% in the nsNSAID group had oligoarthritis.  Naproxen, meloxicam, and nabumetone were the most frequently used nsNSAIDs.  At baseline, the celecoxib group had numerically longer disease duration, was older, and had a higher median weight and height.  This is consistent with the practice of using celecoxib as the second or third NSAID in JIA.  A numerically higher proportion of celecoxib patients had a history of intolerance to nsNSAIDs, mostly due to gastrointestinal side effects.  The analysis of AEs reported during the study showed a similar incidence of AEs across groups (44 and 53/100 PYO for nsNSAID and celecoxib respectively, and 50/100 PYO for those off-NSAID [≥29 days after final dose]).  AEs were those frequently observed with NSAID treatment.  Two patients on nsNSAID and 2 off-NSAID experienced AEs of special interest.  Twelve unique patients experienced a total of 18 serious adverse events (SAEs), the most frequent of which were infections; none were attributed to NSAID.  Incidence rates (95% CI) of SAEs per 100 PYO were 3.4 (1.2, 5.6) and 2.9 (0, 7.0) for the nsNSAID and celecoxib group respectively, and 4.0 (0, 8.6) for the off-NSAID cohort.  Overall, the study results indicate no important difference in the safety profiles between celecoxib and nsNSAIDs.

Conclusion: The total study population of 274 patients followed for a total of 410 PYO is one of the largest JIA NSAID cohorts, and adds substantially to the safety experience of NSAID treatment of JIA.  The safety profile of celecoxib appears similar overall to that of nsNSAIDs and the benefit-risk for celecoxib treatment in JIA remains positive.


Disclosure:

R. E. Sobel,

Pfizer Inc,

3;

D. J. Lovell,

Centocor, Inc.,

5,

AstraZeneca,

5,

Wyeth Pharmaceuticals,

8,

Amgen,

9,

Bristol-Myers Squibb,

5,

Abbott Immunology Pharmaceuticals,

5,

Pfizer Inc,

5,

Regeneron,

5,

Hoffmann-La Roche, Inc.,

5,

Novartis Pharmaceutical Corporation,

5,

Forest Laboratories,

9,

horizon pharmaceuticals,

5;

H. Brunner,
None;

J. E. Weiss,
None;

P. W. Morris,
None;

B. S. Gottlieb,

Pfizer Inc,

5;

E. C. Chalom,
None;

L. K. Jung,
None;

K. Onel,
None;

L. Petinoit,
None;

D. P. Goldsmith,
None;

S. Abramsky-Risman,
None;

J. P. Young,
None;

E. H. Giannini,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-celecoxib-and-non-selective-non-steroidal-anti-inflammatory-drugs-in-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology